WEBULL
WebtradeDownload

Immunovant (IMVT) On IMVT 1402 Progress Is Fair Value Starting To Look Reachable

Simply Wall St · 1d ago

Immunovant (IMVT) has drawn fresh attention after management outlined progress and plans for its anti FcRn therapy IMVT-1402, highlighting upcoming clinical readouts, regulatory milestones through 2028, and readiness for potential commercial launches.

See our latest analysis for Immunovant.

At a share price of US$41.82, Immunovant has seen solid momentum build, with a 90 day share price return of 52.13% and a 1 year total shareholder return of 174.77%, as investors respond to IMVT-1402 updates and upcoming clinical milestones.

If you are looking beyond Immunovant in autoimmune and biotech, this is a useful moment to see what other healthcare AI focused companies are doing through the 44 healthcare AI stocks

Bulls see Immunovant’s clinical pipeline and first to market potential in Graves’ disease as justification for the recent share price surge. Bears point to ongoing losses and execution risk. Which side does the current valuation lean toward as you look at the numbers?

Most Popular Narrative: 13% Undervalued

Immunovant’s most followed narrative pegs fair value at about $48 per share, above the last close at $41.82. That gap puts the focus on what needs to go right in the pipeline.

The planned pivotal Graves' disease data for IMVT-1402 in 2027 targets a large population with ongoing unmet need, so any move toward long term treatment or remission oriented use could diversify Immunovant’s future revenue mix and spread fixed costs over a broader base, supporting net margin efficiency.

Read the complete narrative.

Curious what underpins that target for Immunovant. The narrative leans on steep revenue expansion, a shift from heavy losses toward healthier margins, and a rich future earnings multiple. Want to see which assumptions carry the most weight in that fair value story.

Result: Fair Value of $48.07 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Immunovant story still hinges on IMVT-1402 trial outcomes and future financing needs, either of which could challenge the current fair value narrative.

Find out about the key risks to this Immunovant narrative.

Another View On Immunovant’s Valuation

The first narrative presents Immunovant as about 13% undervalued around a fair value of $48.07. A second lens looks at price against book value. Immunovant trades on a P/B of 11.7x versus 2.5x for the wider US Biotechs group and 22.8x for its peer set. That suggests the stock is expensive relative to the industry but cheaper than closer comparables, which raises a clear question: Is the premium to the sector a potential concern for you, or a price you are willing to pay for IMVT-1402 exposure?

For a closer look at how this ratio-based view compares, including where the market could move toward a fair ratio over time, See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:IMVT P/B Ratio as at Aug 2026
NasdaqGS:IMVT P/B Ratio as at Aug 2026

Next Steps

If the mixed sentiment around Immunovant leaves you on the fence, this is the moment to move quickly, weigh the upside and downside, and stress test the numbers for yourself. To help frame both sides of the argument, start with the 1 key reward and 5 important warning signs

Looking for more investment ideas beyond Immunovant?

Once you have formed a view on Immunovant, do not stop there. Broader context across other stocks can sharpen your conviction and highlight fresh opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.